These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1718 related items for PubMed ID: 17823083

  • 1. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z.
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [Abstract] [Full Text] [Related]

  • 2. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.
    Hansdóttir H, Franzson L, Prestwood K, Sigurdsson G.
    J Am Geriatr Soc; 2004 May; 52(5):779-83. PubMed ID: 15086661
    [Abstract] [Full Text] [Related]

  • 3. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL, He JW, Qin YJ, Huang QR, Liu YJ, Hu YQ, Li M.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [Abstract] [Full Text] [Related]

  • 4. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis.
    Shaarawy M, Zaki S, Sheiba M, El-Minawi AM.
    Clin Lab; 2003 Apr; 49(11-12):625-36. PubMed ID: 14651333
    [Abstract] [Full Text] [Related]

  • 5. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [Abstract] [Full Text] [Related]

  • 6. Possible pathogenetic role of new cytokines in postmenopausal osteoporosis and changes during calcitonin plus calcium therapy.
    Gür A, Denli A, Nas K, Cevik R, Karakoc M, Sarac AJ, Erdogan F.
    Rheumatol Int; 2002 Sep; 22(5):194-8. PubMed ID: 12215865
    [Abstract] [Full Text] [Related]

  • 7. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.
    D'Amelio P, Muratore M, Tinelli F, Tamone C, Cosentino L, Quarta E, Calcagnile F, Carlo Isaia G.
    Int J Tissue React; 2003 Sep; 25(2):73-8. PubMed ID: 14518596
    [Abstract] [Full Text] [Related]

  • 8. Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels.
    Uebelhart B, Herrmann F, Pavo I, Draper MW, Rizzoli R.
    J Bone Miner Res; 2004 Sep; 19(9):1518-24. PubMed ID: 15312253
    [Abstract] [Full Text] [Related]

  • 9. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harpe K.
    Zhonghua Yi Xue Za Zhi; 2004 Feb 17; 84(4):269-73. PubMed ID: 15059505
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Short-term oral magnesium supplementation suppresses bone turnover in postmenopausal osteoporotic women.
    Aydin H, Deyneli O, Yavuz D, Gözü H, Mutlu N, Kaygusuz I, Akalin S.
    Biol Trace Elem Res; 2010 Feb 17; 133(2):136-43. PubMed ID: 19488681
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men.
    Doran PM, Riggs BL, Atkinson EJ, Khosla S.
    J Bone Miner Res; 2001 Nov 17; 16(11):2118-25. PubMed ID: 11697809
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The "lively" cytokines network in beta-Thalassemia Major-related osteoporosis.
    Morabito N, Russo GT, Gaudio A, Lasco A, Catalano A, Morini E, Franchina F, Maisano D, La Rosa M, Plota M, Crifò A, Meo A, Frisina N.
    Bone; 2007 Jun 17; 40(6):1588-94. PubMed ID: 17412659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 86.